评论
打印
China will make more cancer drugs affordable, as a new round of negotiations between the country's state medical insurance administration and pharmaceutical companies to add such drugs to the medical insurance list is scheduled to finish by the end of September.
随着国家医疗保障局和药企展开新一轮抗癌药医保准入谈判，我国将使更多抗癌药能为人们所负担。谈判工作预计将于9月底前完成。
The administration said it has selected a range of drugs to be added and is confirming the producers' willingness to further negotiate.
国家医保局称，已遴选一系列拟纳入医保的药品，目前正与药企确认进一步的谈判意愿。
All of these drugs are of great clinical value and will bring huge benefits to patients with different blood cancers or solid tumors, including colorectal cancer, renal cell carcinoma, lymphoma, and chronic myelogenous leukemia, said the administration.
该机构表示，所有拟谈判的药品均具有较高的临床价值，将为患有结直肠癌、肾细胞癌、淋巴癌、多发性骨髓瘤等不同血液肿瘤或实体肿瘤的患者带来极大的益处。
China has exempted import tariffs from all common drugs including cancer drugs, cancer alkaloid-based drugs, and imported traditional Chinese medicine since May 1.
自5月1日以来，中国已免除了包括抗癌药在内的所有普通药品、具有抗癌作用的生物碱类药品及有实际进口的中成药的进口关税。
Based on the new policy, 12 pharmaceutical companies have recalculated the prices of their products and will submit applications for price adjustments based on the requirements of the administration.
根据新政，12家药企已对药品价格进行重新测算，并将根据国家医保局的要求提交药价调整申请。
A negotiation launched in 2017 has lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.
于2017年启动的一项谈判，降低了15种疗效确切但价格较为昂贵的癌症治疗药品的价格，如赫普丁、利妥西单抗和硼替佐米，并将这些药物添加到医疗保险报销单中。
